


Study shows novel agent can overcome immune dysfunction in cancer

October 6 2022



VSSP restores myeloid cell frequencies following leukopenia. C57BL/6 mice were injected with CY (200 mg/kg body weight, i.p.) and with two consecutive

daily doses of G-CSF (300 $\mu\text{g}/\text{kg}$ of body weight, s.c.), one dose of VSSP (200 μg , s.c.), or both VSSP and G-CSF starting 2 days after CY treatment (A). Total BM cells (B) and GMP and MegE (C) were determined by cell count and flow analysis of the BM respectively, 4 days after CY administration (n=3). Levels of oligopotent GMPs, GPs and MPs were also determined (D). Data represent the mean of three individual mice \pm SEM. Results shown are representative of two independent experiments. Asterisks above bars indicate significant differences (* or ** when p

Citation: Study shows novel agent can overcome immune dysfunction in cancer (2022, October 6) retrieved 1 February 2024 from

<https://medicalxpress.com/news/2022-10-agent-immune-dysfunction-cancer.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.